Today’s Food and Drug Administration approval of a supplemental biologics license for the monoclonal antibody omalizumab (Xolair) highlights the vital role of the National Institutes of Health-supported research that underpins the FDA decision.
FDA approves omalizumab for food allergy reactions based on NIH research
- Post author:
- Post published:February 16, 2024
- Post category:uncategorized